Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
CNS Oncology|December 17, 2015
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastomaNa Tosha N Gatson, Shiao-Pei S Weathers, John F de Groot
Advances in Experimental Medicine and Biology|January 1, 2022
Neurologic Toxicities of ImmunotherapyRebecca A Harrison, Nazanin K Majd, Sudhakar Tummala, et al.
Oncotarget|September 13, 2015
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagyJi Liang, Yuji Piao, Verlene Henry, et al.
Neuro-Oncology|November 27, 2018
Disparities along the glioblastoma clinical trials landscapeEthan B Ludmir, Jacob J Mandel, Mary Frances McAleer, et al.
Cancer Research|March 9, 2005
The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivoJohn F de Groot, Ta Jen Liu, Gregory Fuller, et al.
Journal of the American Statistical Association|March 9, 2026
Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical TrialsNoirrit Kiran Chandra, Abhra Sarkar, John F de Groot, et al.
Neurology|October 31, 2012
Moving toward molecular classification of diffuse gliomas in adultsBrett J Theeler, W K Alfred Yung, Gregory N Fuller, et al.
Journal of Neuro-Oncology|February 17, 2009
Dapsone induced methemoglobinemia in a patient with glioblastomaJulie G Walker, Tapan Kadia, Latrondria Brown, et al.
Oncotarget|April 7, 2016
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastomaSoon Young Park, Yuji Piao, Craig Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transitionYuji Piao, Ji Liang, Lindsay Holmes, et al.
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
CNS Oncology|December 17, 2015
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastomaNa Tosha N Gatson, Shiao-Pei S Weathers, John F de Groot
Advances in Experimental Medicine and Biology|January 1, 2022
Neurologic Toxicities of ImmunotherapyRebecca A Harrison, Nazanin K Majd, Sudhakar Tummala, et al.
Oncotarget|September 13, 2015
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagyJi Liang, Yuji Piao, Verlene Henry, et al.
Neuro-Oncology|November 27, 2018
Disparities along the glioblastoma clinical trials landscapeEthan B Ludmir, Jacob J Mandel, Mary Frances McAleer, et al.
Cancer Research|March 9, 2005
The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivoJohn F de Groot, Ta Jen Liu, Gregory Fuller, et al.
Journal of the American Statistical Association|March 9, 2026
Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical TrialsNoirrit Kiran Chandra, Abhra Sarkar, John F de Groot, et al.
Neurology|October 31, 2012
Moving toward molecular classification of diffuse gliomas in adultsBrett J Theeler, W K Alfred Yung, Gregory N Fuller, et al.
Journal of Neuro-Oncology|February 17, 2009
Dapsone induced methemoglobinemia in a patient with glioblastomaJulie G Walker, Tapan Kadia, Latrondria Brown, et al.
Oncotarget|April 7, 2016
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastomaSoon Young Park, Yuji Piao, Craig Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2013
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transitionYuji Piao, Ji Liang, Lindsay Holmes, et al.
Pageof 13